Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

OUTLIVE

Financiado

Cerrado

OUTLIVE a disruptive non invasive ultrasound therapy to treat all patients affe...

OUTLIVE a disruptive non invasive ultrasound therapy to treat all patients affected with aortic stenosis. Aortic stenosis (AS) is a life-threatening disease caused by the narrowing of the opening of the aortic valve which is the gateway from the heart to the body. With age, the aortic valve calcifies and stiffens, leading to poor bloo... ver más

30/06/2021

CARDIAWAVE

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

CARDIAWAVE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-06-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

CARDIAWAVE

2.49M€ | Lider

LILLY

3.53M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

InSiDe Integrated silicon photonics for Cardiovascular Disease moni... 6M€ Cerrado

DRAIOCHT DRAIOCHT A low cost minimally invasive platform medical dev... 130K€ Cerrado

ElastoCardioScope An innovative tool for non invasive evaluation of myocardial... 150K€ Cerrado

HEARTMAPAS Single Heart beat MApping of myocardial Performance Activat... 2M€ Cerrado

CARDIS Early stage CARdio Vascular Disease Detection with Integrate... 4M€ Cerrado

TEC2013-49465-EXP DETECCION DE DEFECTOS ESTRUCTURALES POR DETERIORO DE STENTS... 92K€ Cerrado

Duración del proyecto: 33 meses Fecha Inicio: 2018-09-26
Fecha Fin: 2021-06-30

Líder del proyecto

CARDIAWAVE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Aortic stenosis (AS) is a life-threatening disease caused by the narrowing of the opening of the aortic valve which is the gateway from the heart to the body. With age, the aortic valve calcifies and stiffens, leading to poor blood perfusion. It causes heart failure and sudden death. The only medical response to date consists in replacing the aortic valve. It is provided to very sick patients at high risk of sudden death, who represents 25% of all AS patients (6 million in Europe and US). All other affected patients remain untreated. It is an immense unmet medical need. In this context, French medtech Cardiawave has developed a revolutionary solution: Valvosoft, a very innovative real-time image guided medical device for the non-invasive treatment of all AS patients. The device delivers focused high-intensity ultrasounds which repair the aortic valve function. Unlike the current medical solutions, Valvosoft is a non-invasive treatment with low risks, complications and costs. It is a game-changer for patients, physicians and health care establishments because it dramatically changes the way of treating AS throughout the world. It should become a new gold standard: every AS patients will benefit from Valvosoft. Prize-winner of many contests, Cardiawave was created thanks to the combined expertise of an entrepreneur, the Institut Langevin, world leader in ultrasound imaging & therapy and cardiologists from HEGP hospital. The OUTLIVE project will allow Cardiawave to refine current go-to-market strategy and develop an investor ready business plan following CE-mark. Valvosoft clinical safety and efficacy will be demonstrated and reliable trust relation with early-adopters will be established. OUTLIVE will accelerate the scalable Valvosoft commercialisation and enable Cardiawave to become the future leader in non-invasive therapy with expected cumulative revenues exceeding €1.1bn by 2030 and more than 100 new European jobs created.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores